CSL Limited Annual Report 2022/23 55 In 2022/23, CSL’s investment in humanitarian access programs and product support initiatives totalled US$13.7 million.* In the United States, access programs are critical to patients who are uninsured, underinsured or who cannot afford therapy. As a member of the International Federation of Pharmaceutical Manufacturers Association (IFPMA), CSL Seqirus contributed to the development of the Berlin Declaration, which draws on the lessons learned from the COVID-19 pandemic and sets out an approach for more equitable pandemic preparedness and response and calls for contributions from a global collaboration of public, private and charitable sectors together with civil society. The Berlin Declaration is being used in discussions with WHO and Member States as they negotiate a new Pandemic Accord and describes key enablers to equitable access across low-, middle- and high-income countries, including respect for intellectual property rights, robust surveillance and rapid sharing of pathogens, regulatory speed, country readiness and maintaining open borders. US$13.7 million supporting product access across the world* CSL is also committed to pricing practices that reflect the value our products bring to patients and society. To that end, we evaluate real-world and clinical trial data that demonstrate the clinical benefits our therapies deliver, as well as the cost savings they provide to overall healthcare. We also consider patient needs and preferences and how our therapies improve patients’ quality of life and productivity. *Limited assurance by Ernst & Young. Dollar value is a subset of CSL’s total community contributions. In support of our focus areas for improved access to our therapies, last year, CSL Behring announced a significant new partnership with the World Federation of Haemophilia (WFH). In 2023, CSL began its five-year commitment to donating 100 million international units (IUs) of coagulation factor therapy per year for five years to the WFH as part of CSL’s continued support of the WFH Humanitarian Aid Program. The donation, which includes product specifically manufactured for the purposes of being donated, will have a standard shelf life of three years, enabling greater access to these life-saving therapies for people around the world. In January 2023, CSL Behring initiated the first of two deliveries of 50 million IUs to the WFH. The donation is destined to help people living with a bleeding disorder (haemophilia A) in more than 60 developing countries. In addition to the product donation, CSL Behring provided financial support for logistics costs and training programs designed to address unmet needs for people living with haemophilia who are undiagnosed, untreated or undertreated. CSL Behring’s contributions to the WFH Humanitarian Aid programmake life-changing improvement to people with no access to care for bleeding disorders. For example, CSL Behring’s 2022 WFH Stewardship Report outlines the following impact (data based on donations received in calendar year 2022, prior to commencement of CSL's new five-year commitment): 15,601,000 IUs of coagulation factor donated 18 developing countries in receipt of CSL Behring’s donated coagulation factors including, Afghanistan, Angola, Bangladesh, Cuba, El Salvador, Eritrea, Gambia, Ghana, India, Jordan, Lebanon, Mongolia, Nepal, Palestine, Rwanda, Sri Lanka, Syria and Zambia 9,375 patients treated (cumulative from 2016) In 2022 4,219 patients treated (in calendar year 2022) 474 surgeries supported 1,474 patients on prophylaxis (to prevent bleeds) 6,705 acute bleeds treated Improving access in developing countries for patients with bleeding disorders To learn more about the WFH Humanitarian Aid Program, please visit wfh.org/humanitarian-aid
RkJQdWJsaXNoZXIy MjE2NDg3